Evaxion Biotech (EVAX) announces business update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Evaxion announces business update and first quarter 2025 financial results
May 27, 2025 7:30 AM EDTCOPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and announces first quarter 2025 financial results.
Business highlights (since last quarterly update)
Evaxion has made good progress with continued execution of our strategy and plans. We have achieved the first two milestones for the year and are tracking towards future milestones and value catalysts. Highlights include:
